Deibel, Elisabeth;
Carreira, Patricia E;
Vonk, Madelon;
Del Papa, Nicoletta;
Bečvář, Radim;
Guillén-Del-Castillo, Alfredo;
Campochiaro, Corrado;
... Hoffmann-Vold, Anna-Maria; + view all
(2024)
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis Care & Research
, 76
(1)
pp. 88-97.
10.1002/acr.25226.
Preview |
Text
Denton_Arthritis Care Research - 2023 - Deibel - Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over.pdf Download (860kB) | Preview |
Abstract
OBJECTIVE: Outcome of COVID-19 patients improved over the pandemic, including patients with systemic rheumatic diseases. However, data on systemic sclerosis (SSc) patients are lacking. This study aimed to assess the outcome of SSc patients with COVID-19 over several waves. METHODS: SSc patients with COVID-19 registered in the European Scleroderma Trials and Research group (EUSTAR) were collected between April 2020 and April 2021. Patients were assigned to wave 1 to 3 depending on date of COVID-19. Primary endpoints were death, intensive care unit stay or ventilatory support (severe outcome). Subgroup analyses of patients who were hospitalized or died were conducted. General and SSc-specific characteristics and treatment were compared over the waves. Descriptive statistics and multivariate logistic regression were applied. RESULTS: 333 patients were included; 57 patients (17%) had a severe outcome, and 30 patients died (9%). Compared to wave 1, significantly fewer SSc patients suffered from severe COVID-19 in wave 2 and 3 (28.2% vs. 9.8% and 12.7%; p<0.001), less patients required hospitalization (46.7% vs. 19.6% and 25.5%; p<0.001) or ventilatory support (24.0% vs. 8.7% and 10.9%; p=0.001) and fewer patients died (15.7% vs. 5.0% and 7.5%; p=0.011). Patients were significantly younger, more often male, had less frequently arterial hypertension and less SSc cardiac involvement over wave 1 to 3. Patients received significantly less medium to high dose corticosteroids as SSc treatment. CONCLUSIONS: Outcome of SSc patients with COVID-19 improved significantly over time, due to intrinsic and extrinsic factors.
| Type: | Article |
|---|---|
| Title: | Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/acr.25226 |
| Publisher version: | https://doi.org/10.1002/acr.25226 |
| Language: | English |
| Additional information: | © 2023 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10176293 |
Archive Staff Only
 |
View Item |
